Phase I Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, With or Without FOLFIRI, in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts
Summary
The purpose of this phase I study is to evaluate the safety of RGX-202-01 alone or in combination with FOLFIRI in patients with gastrointestinal cancer, including pancreatic cancer.
General Information
NCT#: NCT03597581
Study ID: RGX-202-001
Trial Phase: Phase I
Trial Sponsor: Rgenix, Inc.
Therapies Used in This Trial: Fluorouracil, Irinotecan, Leucovorin, FOLFIRI, RGX-202-01